Walleye Capital LLC Takes $157,000 Position in INmune Bio, Inc. (NASDAQ:INMB)

Walleye Capital LLC acquired a new stake in INmune Bio, Inc. (NASDAQ:INMB - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 33,719 shares of the company's stock, valued at approximately $157,000. Walleye Capital LLC owned approximately 0.15% of INmune Bio at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of INMB. Raymond James Financial Inc. bought a new position in INmune Bio during the fourth quarter worth about $2,221,000. Geode Capital Management LLC increased its stake in INmune Bio by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 363,602 shares of the company's stock valued at $1,698,000 after purchasing an additional 19,136 shares in the last quarter. State Street Corp boosted its position in shares of INmune Bio by 35.1% during the third quarter. State Street Corp now owns 226,428 shares of the company's stock worth $1,220,000 after purchasing an additional 58,838 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in INmune Bio by 73.3% during the fourth quarter. Renaissance Technologies LLC now owns 185,800 shares of the company's stock worth $868,000 after acquiring an additional 78,600 shares in the last quarter. Finally, Westside Investment Management Inc. increased its stake in INmune Bio by 26.2% during the 4th quarter. Westside Investment Management Inc. now owns 89,975 shares of the company's stock worth $420,000 after purchasing an additional 18,660 shares in the last quarter. 12.72% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on INMB. Maxim Group raised their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Rodman & Renshaw assumed coverage on INmune Bio in a research note on Tuesday, January 28th. They issued a "buy" rating and a $23.00 price target on the stock. RODMAN&RENSHAW raised INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Scotiabank lifted their target price on INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a research report on Tuesday, February 11th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, INmune Bio currently has an average rating of "Buy" and an average target price of $22.80.

INmune Bio Stock Up 3.6 %

Shares of NASDAQ:INMB traded up $0.27 during midday trading on Friday, reaching $7.86. The company had a trading volume of 74,185 shares, compared to its average volume of 251,134. INmune Bio, Inc. has a 1-year low of $4.32 and a 1-year high of $11.99. The stock has a market cap of $180.65 million, a PE ratio of -3.60 and a beta of 1.86. The business's 50 day moving average price is $7.76 and its 200 day moving average price is $6.77.

INmune Bio (NASDAQ:INMB - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.14. On average, research analysts expect that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.